WuXi expanding to manufacture CAR T immunotherapies

WuXi PharmaTech Inc. (NYSE:WX) disclosed the cell therapy manufacturing facility it will build in the U.S. will provide clinical- and commercial-scale production of chimeric antigen receptor T (CAR T) cells as well as other cancer immunotherapies.

The 145,000-square-foot cGMP facility in Philadelphia, which WuXi formally announced on Wednesday, is designed for cell therapy products that contain viral vectors such as CAR T cell therapies, which are T cells harvested from a patient's body, engineered to target specific cancers, and then reintroduced into the body. Given the complexity, manufacturing will be a key success factor for these personalized therapies. ...